JP7397797B2 - 治療用化合物および組成物 - Google Patents

治療用化合物および組成物 Download PDF

Info

Publication number
JP7397797B2
JP7397797B2 JP2020542552A JP2020542552A JP7397797B2 JP 7397797 B2 JP7397797 B2 JP 7397797B2 JP 2020542552 A JP2020542552 A JP 2020542552A JP 2020542552 A JP2020542552 A JP 2020542552A JP 7397797 B2 JP7397797 B2 JP 7397797B2
Authority
JP
Japan
Prior art keywords
composition
compound
formula
subject
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512894A (ja
JP2021512894A5 (cg-RX-API-DMAC7.html
Inventor
バートランド エル. チェナード,
ユエリアン シュー,
フランス エル. スタッセン,
ニール ジェイ. ヘイワード,
ジヤオ テン,
Original Assignee
エクセセーラ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセセーラ ファーマシューティカルズ インコーポレイテッド filed Critical エクセセーラ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021512894A publication Critical patent/JP2021512894A/ja
Publication of JP2021512894A5 publication Critical patent/JP2021512894A5/ja
Priority to JP2023203652A priority Critical patent/JP2024023490A/ja
Application granted granted Critical
Publication of JP7397797B2 publication Critical patent/JP7397797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020542552A 2018-02-07 2019-02-04 治療用化合物および組成物 Active JP7397797B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023203652A JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627435P 2018-02-07 2018-02-07
US62/627,435 2018-02-07
PCT/US2019/016503 WO2019156929A1 (en) 2018-02-07 2019-02-04 Therapeutic compounds and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023203652A Division JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Publications (3)

Publication Number Publication Date
JP2021512894A JP2021512894A (ja) 2021-05-20
JP2021512894A5 JP2021512894A5 (cg-RX-API-DMAC7.html) 2022-02-14
JP7397797B2 true JP7397797B2 (ja) 2023-12-13

Family

ID=67548561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542552A Active JP7397797B2 (ja) 2018-02-07 2019-02-04 治療用化合物および組成物
JP2023203652A Pending JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023203652A Pending JP2024023490A (ja) 2018-02-07 2023-12-01 治療用化合物および組成物

Country Status (10)

Country Link
US (2) US11691962B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749662A4 (cg-RX-API-DMAC7.html)
JP (2) JP7397797B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200118088A (cg-RX-API-DMAC7.html)
CN (1) CN111902404A (cg-RX-API-DMAC7.html)
AU (1) AU2019217366B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016123A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089970A1 (cg-RX-API-DMAC7.html)
IL (2) IL276563B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019156929A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
WO2019156929A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530137A (ja) 2009-06-16 2012-11-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体
JP2017507933A (ja) 2014-02-07 2017-03-23 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
WO1999037668A1 (de) 1998-01-26 1999-07-29 Basf Aktiengesellschaft Thrombininhibitoren
US6335324B1 (en) 1998-06-25 2002-01-01 Bristol-Myers Squibb Co. Beta lactam compounds and their use as inhibitors of tryptase
CA2336003A1 (en) 1998-06-25 1999-12-29 Zhongmin Xu Amidino and guanidino azetidinone tryptase inhibitors
WO2000005204A1 (en) 1998-07-23 2000-02-03 Shionogi & Co., Ltd. MONOCYCLIC β-LACTAM COMPOUNDS AND CHYMASE INHIBITORS CONTAINING THE SAME
KR20060120601A (ko) 2003-08-22 2006-11-27 데이진 화-마 가부시키가이샤 키마제 저해제를 유효 성분으로서 함유하는 약제
CA2648522A1 (en) 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
JP5844287B2 (ja) 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのマクロ環
LT2766346T (lt) 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US20190315711A1 (en) 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2019156929A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
CA3117549A1 (en) 2018-10-30 2020-05-07 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
CA3117470A1 (en) 2018-10-30 2020-05-07 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions
KR20210119432A (ko) 2019-01-29 2021-10-05 엑시테라 파마슈티컬스 인코퍼레이티드 치료 화합물 및 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530137A (ja) 2009-06-16 2012-11-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体
JP2017507933A (ja) 2014-02-07 2017-03-23 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物

Also Published As

Publication number Publication date
AU2019217366A1 (en) 2020-08-20
EP3749662A4 (en) 2021-07-14
IL276563B1 (en) 2026-01-01
IL325484A (en) 2026-02-01
US12152014B2 (en) 2024-11-26
US20210188812A1 (en) 2021-06-24
RU2020129237A (ru) 2022-03-09
AU2019217366B2 (en) 2024-07-11
JP2021512894A (ja) 2021-05-20
IL276563B2 (en) 2026-05-01
CA3089970A1 (en) 2019-08-15
KR20200118088A (ko) 2020-10-14
JP2024023490A (ja) 2024-02-21
EP3749662A1 (en) 2020-12-16
IL276563A (en) 2020-09-30
CN111902404A (zh) 2020-11-06
WO2019156929A1 (en) 2019-08-15
US20240059670A1 (en) 2024-02-22
BR112020016123A2 (pt) 2021-02-23
US11691962B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
US12084414B2 (en) Therapeutic compounds and compositions
US20210261524A1 (en) Therapeutic compounds and compositions
JP2024023490A (ja) 治療用化合物および組成物
WO2018118705A1 (en) Therapeutic compounds and compositions
RU2817800C2 (ru) Терапевтические соединения и композиции
HK1230083B (en) Therapeutic compounds and compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231201

R150 Certificate of patent or registration of utility model

Ref document number: 7397797

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150